Headline results for the fourth quarter:
Revenue: JPY 354.3 billion ($2.6 billion), up 16.6%
Loss: JPY 46.1 billion ($345 million)
Note: All changes are versus the prior-year period unless otherwise stated
Astellas noted that sales of its main products including Xtandi, Padcev, Xospata showed "steady growth" during the fourth quarter, while revenue from Evenity in Japan also increased. The company explained that the loss in the three-month period was due to an impairment loss of JPY 60.3 billion. Astellas said earlier this month that "considering the sales situation" for Evrenzo in Japan and Europe, it will book an impairment loss of approximately JPY 45 billion, as well as JPY 8.6 billion after terminating the development of FX-322 and JPY 4.7 billion for ending an agreement with Adaptimmune Therapeutics. Xtandi: JPY 149.3 billion, up 21.6%
Betanis, Myrbetriq and Betmiga: JPY 47.5 billion, up 4.8% Prograf: JPY 47.1 billion, up 6.5%
Padcev: JPY 11.4 billion, up 58.6%
Xospata: JPY 10.3 billion, up 23%
Vesicare: JPY 3.5 billion, down 12.7%
Evrenzo: JPY 800 million, up 58.5%
Full-year revenue: JPY 1.52 trillion, up 17.2%
Full-year profit: JPY 98.7 billion, down 20.4%
Astellas expects revenue for fiscal year 2023 of JPY 1.52 trillion ($11.4 billion), broadly in line with the prior 12-month period, with sales of Xtandi reaching nearly JPY 670 billion ($5 billion), up from JPY 661.1 billion ($4.9 billion). Meanwhile, core profit is seen growing 1.5% to JPY 228 billion ($1.7 billion).